[The action of timoptin peptides on the hemostatic system].

Repeated introduction of thymus polypeptide drug thymoptine (8 times every 24 hours, 1 microgram/kg) led to the increase in total and non-enzymatic fibrinolytic activity of blood plasma and the decrease in fibrinogen concentration. Thymoptine could lyse non-stabilized fibrin and cause depolymerization of aggregates of fibrin monomer in virto. Highest depolymerization activity was observed at thymoptine concentration of 10 micrograms/ml.

[Immunocorrective therapy of patients with rheumatoid arthritis].

The clinico-immunological efficacy is shown of including timoptin, levamysol, sodium nucleinate in the complex treatment of patients with rheumatoid arthritis who received glucocorticosteroids. It was found that employment of immunoregulating agents allowed to correct the immunological insufficiency in patients with rheumatoid arthritis, to increase the treatment efficacy.

[The effect of thymoptin on enzymatic fibrinolysis].

Stimulation of fibrinolysis, decrease in content of fibrinogen and inhibitors were observed after intravenous, intramuscular or subcutaneous administrations of thymoptine preparation (complex of peptides, isolated from mammalian thymus) at doses of 0.1 microgram, 1.0 microgram/200 g of rat body mass.

[Comparative study of the effect of the thymus preparations thymoptin and thymalin on fibrin-monomer polymerization].

Thymoptin was shown to possess the ability of lysis of the nonstabilized fibrin in vitro and of increasing the nonenzymatic fibrinolytic activity of blood plasma after eight daily intramuscular injections to rats in doses of 1 and 100 micrograms/kg body weight and during incubation with purified fibrin monomer to produce its depolymerization. Thymalin possessed no nonenzymatic fibrinolytic activity in vitro and in contrast to thymoptin at a relatively high concentration (1000 and 100 micrograms/ml) enhanced fibrin-monomer polymerization.